Background and Rationale for Revised Clinical and Laboratory Standards Institute Interpretive Criteria (Breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and Aztreonam

被引：115

作者：

Dudley, Michael N. ^{[1
]}

Ambrose, Paul G. ^{[2
]}

Bhavnani, Sujata M. ^{[2
]}

Craig, William A. ^{[3
]}

Ferraro, Mary Jane ^{[4
,5
]}

Jones, Ronald N. ^{[6
]}

机构：

[1] Rempex Pharmaceut, San Diego, CA 92121 USA

[2] Inst Clin Pharmacodynam Inc, Latham, NY USA

[3] Univ Wisconsin, Sch Med, Dept Med, Madison, WI 53706 USA

[4] Massachusetts Gen Hosp, Boston, MA 02114 USA

[5] Harvard Univ, Sch Med, Boston, MA USA

[6] JMI Labs, N Liberty, IA USA

来源：

CLINICAL INFECTIOUS DISEASES | 2013年 / 56卷 / 09期

关键词：

breakpoints; Enterobacteriaceae; cephalosporins; Pseudomonas; CLSI; PHARMACODYNAMICS; INFECTIONS; OUTCOMES;

D O I：

10.1093/cid/cit017

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

071005 [微生物学]; 100108 [医学免疫学];

摘要：

Widespread resistance in Enterobacteriaceae and Pseudomonas aeruginosa to cephalosporin and monobactam antibiotics due to extended-spectrum beta-lactamases (ESBLs) has resulted in the need for reassessment of the interpretative criteria (breakpoints) established for these agents more than 2 decades ago. Following extensive evaluation, the Clinical and Laboratory Standards Institute recently adopted and published new breakpoints for these agents for use in clinical laboratories and provided updated recommendations for use of the ESBL screening test. This paper summarizes the background and supportive rationale for new interpretative criteria for cephalosporins and aztreonam for testing Enterobacteriaceae.

引用

页码：1301 / 1309

页数：9

共 14 条

[1]

Pharmacokinetics-pharmacodynamics of antimicrobial therapy: It's not just for mice anymore [J].